Imunon, Inc. (IMNN) is a clinical-stage biotechnology company with zero product revenue, an accumulated deficit of $426 million at March 31, 2026, and a formal going-concern qualification from its independent auditors. Under a liquidation lens, the recovery picture is deeply negative and deteriorating on a sequential basis. The company reported $4.8 million in cash and cash equivalents at March 31, 2026, down from $10.7 million in total current assets at December 31, 2025 (which included short-term investments beyond cash). Current assets totaled $6.2 million versus current liabilities of $4.2 million at period-end, yielding net working capital of approximately $2.0 million, compared to $6.1 million at year-end 2025 — a $4.1 million sequential decline driven by $4.0 million in operating cash outflows in the quarter. At 100% recovery on cash, the liquidatable asset base is effectively just that $4.8 million cash position plus immaterial other current assets. Intangible assets (primarily capitalized R&D-related IP and platform technology) carry zero recovery value under liquidation haircut assumptions. The company has no inventory, no accounts receivable from product sales, and no PP&E of meaningful scale disclosed. The TAG_CONTEXT provided for this filing contains no XBRL-tagged values, preventing any tag-level balance sheet verification; all figures cited are drawn from the MD&A and footnote prose. The operating lease liability at March 31, 2026 totaled $911,752 (down modestly from $1,008,765 at December 31, 2025 as payments were made), with future undiscounted payments of $1,015,421 through 2028 — this obligation does not extinguish on wind-up and consumes a meaningful portion of the available cash buffer. The company's primary liability stack is the operating lease and accrued current liabilities ($4.2 million total current liabilities). No long-term debt is disclosed. The MFFAIS-derived liquidation value of $3.55 million is consistent with the cash-minus-lease-obligations arithmetic: roughly $4.8 million cash less $0.9 million lease liability less other current obligations approximates that figure. The company is burning approximately $4.0 million per quarter in operating cash, implying less than two quarters of runway at current burn from the March 31, 2026 cash balance. Management's stated plan to raise capital via ATM issuances and other equity transactions is the only disclosed bridge; $417,447 in ATM proceeds were noted as raised subsequent to March 31, 2026 through the filing date, which is de minimis relative to the burn rate. Filing discusses going-concern conditions, Phase 3 clinical trial spend escalation (OVATION program non-clinical R&D up 41.6% QoQ to $1.3 million), and Form S-3 I.B.6 limitations now applying due to public float falling below $75 million — all of which constrain capital-raise flexibility. The filing does not separately tag any balance sheet items in XBRL, making direct tag-level analysis impossible from the TAG_CONTEXT input.
▼ Community Notes